Rev Pneumol Clin
That's not long-term data by the standards of chronic disease management
Circulation 143 , 11571172 (2021)
Some GLP-1 and dual incretin medicines already have approved uses in certain jurisdictions for type 2 diabetes, chronic weight management, or both
30 GLP-1 has been shown to exert various anti-inflammatory actions on different tissues and can potentially be used for the treatment of several chronic inflammatory conditions like atherosclerosis, neurodegenerative disorders, diabetic nephropathy, asthma, psoriasis, and nonalcoholic steatohepatitis
As the active ingredient in the GLP-1 drugs Rybelsus, Ozempic , and Wegovy , semaglutide can produce transformational results